<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-XFRU0B80</identifier><date>2017</date><creator>Kenig, Saša</creator><relation>documents/doc/X/URN_NBN_SI_doc-XFRU0B80_001.pdf</relation><relation>documents/doc/X/URN_NBN_SI_doc-XFRU0B80_001.txt</relation><format format_type="issue">3</format><format format_type="volume">68</format><format format_type="type">article</format><format format_type="extent">str. 203-209</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">1539529668</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-XFRU0B80</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">homologna rekombinacija</subject><subject language_type_id="slv">olaparib</subject><subject language_type_id="slv">rak</subject><subject language_type_id="slv">sintezna smrtnost</subject><subject language_type_id="slv">zaviralci PARP</subject><title>Poly(adenosine diphosphate.ribose) polymeraseinhibitors in cancer therapy</title><title>Zaviralci poli(adenozin difosfat-riboza) polimeraze pri zdravljenju raka</title></Record>